These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 873714)

  • 21. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 24. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 25. [Growth hormone secretion induced by L-Dopa and a dopa decarboxylase inhibitor blocked by free fatty acids].
    Casanueva F; Villanueva L; Peñalva A; Barrionuevo JA; Vila T; Cabezas-Cerrato J
    Rev Clin Esp; 1979 May; 153(3):221-4. PubMed ID: 482695
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TSH and prolactin stimulation by the decarboxylase inhibitor benserazide in primary hypothyroidism.
    Delitala G; Devilla L; Lotti G
    Clin Endocrinol (Oxf); 1980 Mar; 12(3):313-6. PubMed ID: 7389157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients.
    Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B
    Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669
    [No Abstract]   [Full Text] [Related]  

  • 31. [Combined (surgical and drug) therapy of parkinsonism].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
    Boismare F; Boquet J
    Br Med J; 1975 Mar; 1(5957):573. PubMed ID: 1139159
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 35. Increase in plasma 3,4-dihydroxyphenylalanine (DOPA) appearance rate after inhibition of DOPA decarboxylase in humans.
    Eldrup E; Hetland ML; Christensen NJ
    Eur J Clin Invest; 1994 Mar; 24(3):205-11. PubMed ID: 8033956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
    Boismare F; Boquet J; Lefrançois J; Le Poncin M
    Agressologie; 1977; 18(5):285-6. PubMed ID: 602991
    [No Abstract]   [Full Text] [Related]  

  • 37. L-dopa and benserazide in the treatment of acute hepatic encephalopathy in infancy.
    Sinniah D; Chan LL
    Singapore Med J; 1980 Aug; 21(4):658-60. PubMed ID: 7221579
    [No Abstract]   [Full Text] [Related]  

  • 38. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
    Polleri A; Masturzo P; Murialdo G; Carolei A
    Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.